Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancer

Urologic Oncology

Volumn 3, Issue 1, 1997, Pages 18-26

  Persad, R ^a   Fleming, C ^b   Chern, H D ^c   Lesnick, T ^c   Collins, C ^a   Smith, P ^a   Schwartz, A G ^d   Adedoyin, A ^c   Romkes, M ^c,e   Wilkinson, G R ^b   Branch, R A ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d ALLEGHENY SINGER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Bladder cancer; CYP3A4; Cytochrome P450; Dapsone; Susceptibility risk factor

Indexed keywords

CARCINOGEN; DAPSONE; DEBRISOQUINE; GLUTATHIONE TRANSFERASE; MEPHENYTOIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RISK; CANCER SUSCEPTIBILITY; DRUG HYDROXYLATION; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; SMOKING; STATISTICAL ANALYSIS;

EID: 0030725940     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(97)00019-7     Document Type: Article

References (43)

1. Boring C, Squires T, Tong T. Cancer statistics 1991. Cancer J Clin 1991;41:19-37.
2. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hemat Onc Clinics of N Am 1992;6:1-30.
3. Lower GM. Concepts in causality: Chemically induced human bladder cancer. Cancer 1982;49:1056-66.
4. Uehleke H. N-hydroxylation. Xenobiotica 1971;l:327-8.
5. Weisburger JH, Weisburger EK. Biochemical formation and pharmacological, toxicological and pathological properties of hydroxylamines and hydroxamic acids. Pharm Rev 1973;25:1-66.
6. Evans DAP, Eze LC, Whibley EJ. The association of the slow acetylator phenotype with bladder cancer. J Med Genetics 1983;20:330-3.
7. Kaisary A, Smith P, Jacqz E, et al. Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987;47:5488-93.
8. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
9. Wedlund PJ, Aslanian WA, Jacqz E, McAllister CB, Branch RA, Wilkinson GR. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharm Exp Ther 1985;234:662-9.
10. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Review 1985;37:25-79.
11. Brian WR, Sari MA, Iwasaki M, et al. Catalytic activities of human liver cytochrome P4503A4 expressed in Saccharomyces cervesiae. Biochem 1990;29:11280-92.
12. Shimada T, Guengerich FP. Evidence for cytochrome P450NF, the nifedipine oxidase, being the principle enzyme in the bioactivation of aflatoxins in human liver. Proc Natl Acad Sci 1989;86:462-5.
13. Fleming CM, Branch RA, Wilkinson GR, Guengerich FP. Human liver microsomal N-hydroxylation of dapsone by cytochrome P4503A4. Mol Pharmacol 1992;41:975-80.
14. May G, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther 1990;48:619-27.
15. May DG, Arns PA, Richards WO, et al. Influence of cirrhosis on the disposition of dapsone. Clin Pharmacol Ther 1992;51:689-700.
16. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity in a Caucasian population. Clin Pharmacol Ther 1994;55:492-500.
17. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. International Classification of Tumours, No. 10. Geneva: World Health Organization, 1973.
18. Fleming CM, Persad R, Kaisary A, et al. Low activity of dapsone hydroxylation as a susceptibility risk factor in aggressive bladder cancer. Pharmacogenetics 1994;4:199-207.
19. Hermanek P, Sobin LH. International union against cancer (UICC): TNM Classification of Malignant Tumors, 4th ed., Berlin: Springer-Verlag, 1987.
20. Frye RF, Matzke GR, Stiff DD, et al. Validation of a five drug cocktail for use in population phenotyping. Pharm Res 1993; 10:S388.
21. Pearson WS, Hartley HO. Biometrica Tables for Statisticians. Vol 2. Cambridge: Cambridge University Press, 1972.
22. Snecdecor GW, Cochrane WG. Normal distribution. In: Statistical Methods, 7th ed. Ames, IA: Iowa State University Press, 1980.
23. Breslow WE, Day NE. Statistical methods. In: Cancer Research, Vol. 1. Lyon, France: IARC Scientific Publications, 1980;70,192-247.
24. Matthews DE, Farewell VT. Understanding and Using Medical Statistics. New York: S. Karger, 1985.
25. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin N Am 1992;6:1-30.
26. Swoboda H, Friedl HP. Tobacco-related cancer in relation to prevalence of drinking and smoking in eastern Austria. J Cancer Res Clin Oncol 1992;118:621-5.
27. Kunze E, Chang-Claude J, Frentzel-Beyme R Life style and occupational risk factors for bladder cance in Germany. A case-control study. Cancer 1992;69:1776-90.
28. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of diet, smoking, and lower urinary tract cancer. Annals of Epidemiology 1993;3:211-6.
29. Momas I, Daures JP, Festy B, Bontoux J, Gremy F. Relative importance of risk factors in bladder carcinogenesis: Some new results about Mediterranean habits. Cancer Causes & Control 1994;5:326-32.
30. Sorahan T, Lancashire RJ, Sole G. Urothelial cancer and cigarette smoking: Findings from a regional case-controlled study. Br J Urol 1994;74:753-6.
31. Sturgeon SR, Hartge P, Silverman DT, et al. Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiol 1994;5:218-25.
32. Siemiatycki J, Dewar R, Krewski D, Desy M, Richardson L, Franco E. Are the apparent effects of ciagrette smoking on lung and bladder cancers due to uncontrolled confounding by occupational exposures? Epidemiol 1994;5:57-65.
33. Vineis P, Caporaso N. Tobacco and cancer: Epidemiology and the laboratory. Environ Hlth Perspect 1995;103:156-60.
34. Wynder EL, Goldsmith RG. The epidemiology of blader cancer: A second look. Cancer 1977;40:1246-8.
35. Kroft SH, Oyasu R. Urinary bladder cancer: Mechanisms of development and progression. Lab Invest 1994;71:158-74.
36. Claude J, Kunze E, Frentzel-Beyme R, Paczkowski K, Schneider J, Schubert H. Life-style and occupational risk factors in cancer of the lower urinary tract. Am J Epidemiol 1986;124:577-89.
37. Akdas A, Kirkali Z, Bilir N. Epidemiological case-control study on the aetiology of bladder cancer in Turkey. Eur Urol 1990;17:23-6.
38. Mommsen S, Aagaard J, Sell A. An epiderniological case-control study of bladder cancer in males from a predominantly rural district. Eur J Cancer Clin Oncol 1982;18:1205-10.
39. Thomas DB, Uhl CN, Hartge P. Bladder cancer and alcoholic beverage consumption. Am J Epidemiol 1983;118:720-7.
40. Bravo MP, Del Rey Calero J, Conde M. Bladder cancer and the consumption of alcoholic beverages in Spain. Eur J Epidemiol 1987;3:365-9.
41. Irshaid Y, Adedoyin A, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Drug Metab Disp, submitted.
42. Branch RA, Chern HD, Adedoyin A, et al. The procarcinogen hypothesis for bladder cancer: Activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 1995;5: S97-102.
43. Arns PA, DiBesceglie A, Waggoner JG, Hoffnagle JH, Wilkinson GR, Branch RA. Mephenytoin disposition and serum bile acids as indicies of hepatic function in chronic viral hepatitis. Hepatol, submitted.